Cibc World Market Inc. Sells 29,220 Shares of Zoetis Inc. $ZTS

Posted by Brian Himes on Jun 6th, 2026

Cibc World Market Inc. lowered its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 19.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 121,185 shares of the company’s stock after selling 29,220 shares during the quarter. Cibc World Market Inc.’s holdings in Zoetis were worth $15,247,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Global Wealth Strategies & Associates bought a new position in Zoetis in the 4th quarter worth $25,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis during the 3rd quarter valued at about $31,000. Lodestone Wealth Management LLC bought a new position in shares of Zoetis during the 4th quarter valued at about $30,000. Elyxium Wealth LLC bought a new position in shares of Zoetis during the 4th quarter valued at about $32,000. Finally, Holos Integrated Wealth LLC bought a new position in shares of Zoetis during the 4th quarter valued at about $32,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.0%

Shares of NYSE:ZTS opened at $79.49 on Friday. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 12 month low of $72.38 and a 12 month high of $171.52. The company has a 50-day moving average price of $100.52 and a 200 day moving average price of $115.54. The company has a market cap of $33.33 billion, a price-to-earnings ratio of 13.18, a PEG ratio of 1.24 and a beta of 0.75.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the previous year, the business posted $1.48 EPS. The firm’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Analyst Ratings Changes

Several research analysts have commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. UBS Group dropped their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Morgan Stanley reissued an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. Finally, Stifel Nicolaus dropped their price objective on shares of Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a report on Friday, May 22nd. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis has an average rating of “Hold” and an average price target of $133.92.

Get Our Latest Stock Report on ZTS

Insider Activity at Zoetis

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael B. Mccallister purchased 3,000 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares in the company, valued at $1,906,986.24. The trade was a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 11,650 shares of company stock valued at $886,384. Insiders own 0.22% of the company’s stock.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: Zoetis published the company’s 2025 Sustainability Report, highlighting progress in animal health and its next phase of sustainability goals. Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future
Neutral Sentiment: The stock saw unusual call-option buying, suggesting some traders are positioning for a rebound despite the recent selloff. Zoetis (ZTS) rises as investors refocus on outlook and precision-animal-health expansion
Neutral Sentiment: Zoetis’ valuation is being reassessed after its guidance cut and ongoing concerns about companion-animal demand and legal issues. A Look At Zoetis (ZTS) Valuation After Guidance Cut Legal Actions And Companion Animal Headwinds
Negative Sentiment: Jim Cramer said he prefers Elanco over Zoetis, adding to negative investor sentiment around ZTS. Jim Cramer Recommends Elanco Over Zoetis
Negative Sentiment: Multiple law firms announced or promoted class-action lawsuits against Zoetis, with allegations tied to alleged misleading statements, FDA safety warnings, and market-share erosion. ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
Negative Sentiment: The company is also facing investor-notice deadlines and additional securities-fraud claims, keeping legal overhang front and center for shareholders. INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Zoetis Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.